DK2791674T3 - Fremgangsmåde til screening af forbindelser til behandling af cancer ved inhibering af myd88/erk-map-kinase-interaktion - Google Patents
Fremgangsmåde til screening af forbindelser til behandling af cancer ved inhibering af myd88/erk-map-kinase-interaktion Download PDFInfo
- Publication number
- DK2791674T3 DK2791674T3 DK12808362.3T DK12808362T DK2791674T3 DK 2791674 T3 DK2791674 T3 DK 2791674T3 DK 12808362 T DK12808362 T DK 12808362T DK 2791674 T3 DK2791674 T3 DK 2791674T3
- Authority
- DK
- Denmark
- Prior art keywords
- myd88
- cancer
- dna damage
- selecting
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
1. Fremgangsmåde til udvælgelse af in wfro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer, omfattende følgende trin: a) at tilvejebringe mindst en kandidatforbindelse; b) at bringe mindst en kandidatforbindelse i kontakt med et ERK MAPK-protein og et MyD88-protein under betingelser, der er egnede til at lade ERK MAPK og MyD88 interagere i fravær af kandidatmolekylet; c) at bestemme interaktionen mellem ERK MAPK og MyD88 målt i nærvær og i fravær af mindst en kandidatforbindelse; og d) at udvælge en kandidatforbindelse, der inhiberer interaktionen mellem ERK MAPK og MyD88.
2. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge krav 1, hvor et eller begge af ERK MAPK og MyD88 er knyttet til en detekterbar markering.
3. Fremgangsmåde til udvælgelse af in v/fro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 1-2, hvor interaktionen mellem ERK MAPK og MyD88 bestemmes under anvendelse af et to-hybrid-system, affinitetskromatografi, co-immunpræcipitation, subcellulær fraktionering og isolering af store molekylkomplekser, immunblotting, immunmærkning, et proximity ligation-assay, et immunpræcipitation-assay, et biacore-assay eller et GST pull-down-assay.
4. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 1-3, hvor det DNA-skade-inducerende kemoterapimiddel er udvalgt i gruppen bestående af oxaliplatin, cisplatin, carboplatin, doxorubicin, etoposid, bleomycin og blandinger deraf.
5. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 1-4, hvor canceren er udvalgt i gruppen bestående af kolorektal cancer, tarmkræft, melanom, lungekræft og cervixcancer.
6. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer, omfattende følgende trin: a) at tilvejebringe mindst en kandidatforbindelse; b) at tilvejebringe transformerede celler, der stabilt eksprimerer MyD88 under styring af en inducerbar promoter, og som eksprimerer et reportergen under styring af en promoter fra MAPK-vejen udvalgt blandt SRE-promoteren, ELK-promoteren og MyC-promoteren; c) at inducere overekspression af MYD88 i de transformerede celler i nærvær af mindst en kandidatforbindelse; d) at måle ekspressionen af reportergenet og udvælge mindst en kandidatforbindelse, der inhiberer ekspressionen af reportergenet; e) at tilvejebringe immortaliserede fibroblaster transformeret ved transfektion med MyD88 og Myc-onkogener; f) Monitorering af fokusdannelse i nærvær af mindst en kandidatforbindelse udvalgt i trin d) og i nærvær af mindst et DNA-skade-inducerende kemoterapimiddel og at udvælge en kandidatforbindelse, der potenserer den inhibe-rende virkning af det DNA-skade-inducerende kemoterapimiddel på fokusdannelse.
7. Fremgangsmåde til udvælgelse af in wYro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge krav 6, hvor, i trin b), promoteren fra MAPK-vejen er SRE-promoteren.
8. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-7, hvor fremgangsmåden yderligere omfatter følgende trin: - at tilvejebringe transformerede celler, der stabilt eksprimerer MyD88 under styring af en inducerbar promoter og eksprimerer et reportergen under sty ring af en promoter fra inflammationsvejen udvalgt blandt Nf-kB-promoteren og ISRE-promoteren; - at inducere overekspression af MYD88 i de transformerede celler i nærvær af mindst en kandidatforbindelse; - at måle ekspressionen af reportergenet og udvælge en kandidatforbindelse, som ikke inhiberer ekspressionen af reportergenet.
9. Fremgangsmåde til udvælgelse af in wYro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge krav 8, hvor promoteren fra inflammationsvejen er Nf-kB.
10. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-9, hvor, i trin b), cellerne er udvalgt blandt HCT116-cellelinjen, A375-cellelinjen og en HeLa-cellelinje.
11. Fremgangsmåde til udvælgelse af in vitro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-10, hvor den inducerbare promoter er en antibiotikum-inducerbar promoter.
12. Fremgangsmåde til udvælgelse af in wfro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-11, hvor de immortaliserede fibroblaster er NIFI3T3-immortaliserede fibroblaster.
13. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-12, hvor canceren er udvalgt i gruppen bestående af kolorektal cancer, tarmkræft, melanom, lungekræft og cervixcancer.
14. Fremgangsmåde til udvælgelse af in v/Yro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-13, hvor det DNA-skade-inducerende kemoterapimiddel er udvalgt blandt oxaliplatin, cisplatin, carbo- platin, doxorubicin, etoposid, bleomycin og blandinger deraf.
15. Fremgangsmåde til udvælgelse af in vitro-forbindelser, der kan potensere virkningen af et DNA-skade-inducerende kemoterapimiddel til behandling af cancer ifølge et hvilket som helst af kravene 6-14, hvor kandidatforbindelsen fra trin a) udvælges i henhold til en fremgangsmåde ifølge et hvilket som helst af kravene 1-5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306686 | 2011-12-16 | ||
| PCT/EP2012/075839 WO2013087937A1 (en) | 2011-12-16 | 2012-12-17 | Treatment of cancer by inhibition of the myd88/erk map kinase interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2791674T3 true DK2791674T3 (da) | 2016-10-03 |
Family
ID=47458949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12808362.3T DK2791674T3 (da) | 2011-12-16 | 2012-12-17 | Fremgangsmåde til screening af forbindelser til behandling af cancer ved inhibering af myd88/erk-map-kinase-interaktion |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9683986B2 (da) |
| EP (1) | EP2791674B1 (da) |
| JP (1) | JP6049751B2 (da) |
| KR (1) | KR20140119698A (da) |
| CN (1) | CN104185789B (da) |
| AU (1) | AU2012351486B2 (da) |
| CA (1) | CA2858466C (da) |
| CY (1) | CY1118071T1 (da) |
| DK (1) | DK2791674T3 (da) |
| ES (1) | ES2595408T3 (da) |
| HU (1) | HUE031160T2 (da) |
| IL (1) | IL232842A (da) |
| PL (1) | PL2791674T3 (da) |
| PT (1) | PT2791674T (da) |
| SI (1) | SI2791674T1 (da) |
| WO (1) | WO2013087937A1 (da) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005274985A1 (en) * | 2004-07-19 | 2006-02-23 | Schering Corporation | MyD88 as a therapeutic target for cancer |
| WO2006113530A2 (en) | 2005-04-15 | 2006-10-26 | University Of Maryland, Baltimore | Selective inhibition of tlr4 signaling |
| EP1892301A4 (en) * | 2005-06-07 | 2008-09-17 | Banyu Pharma Co Ltd | METHOD FOR EVALUATING A CONNECTION BY RSK1 |
-
2012
- 2012-12-17 WO PCT/EP2012/075839 patent/WO2013087937A1/en active Application Filing
- 2012-12-17 PL PL12808362T patent/PL2791674T3/pl unknown
- 2012-12-17 KR KR1020147019311A patent/KR20140119698A/ko not_active Application Discontinuation
- 2012-12-17 HU HUE12808362A patent/HUE031160T2/en unknown
- 2012-12-17 ES ES12808362.3T patent/ES2595408T3/es active Active
- 2012-12-17 CA CA2858466A patent/CA2858466C/en active Active
- 2012-12-17 SI SI201230717A patent/SI2791674T1/sl unknown
- 2012-12-17 AU AU2012351486A patent/AU2012351486B2/en active Active
- 2012-12-17 US US14/364,582 patent/US9683986B2/en active Active
- 2012-12-17 CN CN201280069559.9A patent/CN104185789B/zh active Active
- 2012-12-17 EP EP12808362.3A patent/EP2791674B1/en active Active
- 2012-12-17 PT PT128083623T patent/PT2791674T/pt unknown
- 2012-12-17 DK DK12808362.3T patent/DK2791674T3/da active
- 2012-12-17 JP JP2014546573A patent/JP6049751B2/ja active Active
-
2014
- 2014-05-28 IL IL232842A patent/IL232842A/en active IP Right Grant
-
2016
- 2016-10-03 CY CY20161100976T patent/CY1118071T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2791674T1 (sl) | 2016-12-30 |
| EP2791674B1 (en) | 2016-07-06 |
| CA2858466C (en) | 2021-10-19 |
| AU2012351486A1 (en) | 2014-07-31 |
| EP2791674A1 (en) | 2014-10-22 |
| CY1118071T1 (el) | 2017-06-28 |
| PT2791674T (pt) | 2016-10-07 |
| KR20140119698A (ko) | 2014-10-10 |
| US20140329261A1 (en) | 2014-11-06 |
| HUE031160T2 (en) | 2017-06-28 |
| JP6049751B2 (ja) | 2016-12-21 |
| JP2015501939A (ja) | 2015-01-19 |
| PL2791674T3 (pl) | 2017-01-31 |
| US9683986B2 (en) | 2017-06-20 |
| IL232842A (en) | 2017-08-31 |
| WO2013087937A1 (en) | 2013-06-20 |
| AU2012351486B2 (en) | 2018-01-04 |
| IL232842A0 (en) | 2014-07-31 |
| ES2595408T3 (es) | 2016-12-29 |
| CN104185789B (zh) | 2016-08-24 |
| CA2858466A1 (en) | 2013-06-20 |
| CN104185789A (zh) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK) | |
| Lin et al. | Induction of Cbl‐dependent epidermal growth factor receptor degradation in Ling Zhi‐8 suppressed lung cancer | |
| CN111150848B (zh) | Plagl2及其在肝癌中的应用 | |
| Boin et al. | Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas | |
| Chen et al. | Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer | |
| Yang et al. | SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A–c‐Myc axis | |
| Holmes et al. | mTORC2-mediated direct phosphorylation regulates YAP activity promoting glioblastoma growth and invasive characteristics | |
| Montano et al. | WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene | |
| EP3092492B1 (en) | Treatment of tumors expressing mutant p53 | |
| US20210332136A1 (en) | Methods for diagnosing and treating cancers | |
| Lian et al. | miR-25-3p promotes endothelial cell angiogenesis in aging mice via TULA-2/SYK/VEGFR-2 downregulation | |
| Hou et al. | Inhibition of protein PMP22 enhances etoposide-induced cell apoptosis by p53 signaling pathway in Gastric Cancer | |
| Ohta et al. | The role of MerTK in promoting cell migration is enhanced by the oncogenic Ras/IL‐33 signaling axis | |
| Sun et al. | circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2 | |
| US11510911B2 (en) | Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor | |
| KR20190142746A (ko) | Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물 | |
| DK2791674T3 (da) | Fremgangsmåde til screening af forbindelser til behandling af cancer ved inhibering af myd88/erk-map-kinase-interaktion | |
| Liu et al. | CD73 promotes cervical cancer growth via EGFR/AKT1 pathway | |
| EP3211087A1 (en) | Method for screening compound specifically inhibiting formation of caveolae in cancer cells, screening kit, vector and transformant to be used in kit, and method for selecting patient adaptable for molecular-targeting drug | |
| Merkerova et al. | Expression analysis of PCNA gene in chronic myelogenous leukemia—Combined application of siRNA silencing and expression arrays | |
| CA2656577A1 (en) | Method for evaluation of a cancer | |
| Chu et al. | EGF-Activated Grb7 Confers to STAT3-Mediated EPHA4 Gene Expression in Regulating Lung Cancer Progression | |
| US20170315126A1 (en) | Method for screening compound specifically suppressing formation of caveolae of cancer cells, screening kit, vector and transformant to be used in kit, and method for selecting patient for whom molecularly targeted drug is indicated | |
| 신승현 | CITED2 enhances prostate cancer metastasis by activating nucleolin-AKT pathway | |
| WO2013010101A1 (en) | Method of treating and reducing the risk of acute myelogenous leukemia |